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Incorporation of simvastatin in PLLA membranes
for guided bone regeneration: eﬀect of thermal
treatment on simvastatin release†
Antonio G. B. Castro,a Dennis W. P. M. Lo¨wik,c Mies J. van Steenbergen,b
John A. Jansen,a Jeroen J. J. P. van den Beuckena and Fang Yang *a
Electrospun membranes based on biodegradable polymers are promising materials to be used for guided
bone regeneration (GBR) therapy. The incorporation of osteostimulatory compounds can improve the
biofunctionality of those membranes, making them active players in bone regeneration. Simvastatin
has been shown to promote osteogenic diﬀerentiation both in vitro and in vivo. However, in most of
these systems, the drug was quickly released, not matching the pace of bone regeneration. The aim of
this study was to develop poly(L-lactic acid) (PLLA) membranes containing simvastatin (SV) that have
a prolonged drug release rate, compatible with GBR applications. To this end, SV was mixed with PLLA
and electrospun. The membranes were subjected to a thermal treatment in order to increase the
crystallinity of PLLA. Morphological, structural and chemical properties of the electrospun membranes
were characterized. The eﬀect of the thermal treatment on the release proﬁle of SV was evaluated by
near physiological release experiments at 37 C. The osteostimulatory potential was determined by in
vitro culture of the membranes with rat bone marrow stromal cells (rBMSCs). The results conﬁrmed
that the thermal treatment led to an increase in polymer crystallinity and a more sustained release
of SV. In vitro assays demonstrate cellular proliferation over time for all the membranes and
a signiﬁcant increase in osteogenic diﬀerentiation for the membranes containing SV subjected to
thermal treatment.
Introduction
Dental implants are a common treatment option for replacing
missing teeth due to diseases, like periodontitis, or trauma.
Successful implant placement requires adequate alveolar ridge
dimensions, which are essential to house the implant and
provide esthetics and function.1 Unfortunately, this is usually
not the case due to bone resorption or damage. Therefore,
a ridge augmentation technique is oen required to regenerate
enough bone for successful implant placement. Guided bone
regeneration (GBR) is an established strategy for this purpose
and based on the creation of a secluded space, in which
pluripotent and osteogenic cells are allowed to proliferate and
form new bone, whilst so tissue formation (by e.g. broblasts
and epithelial cells) is inhibited.1 This can be achieved by
a physical barrier, mainly in the form of a membrane.2,3
Electrospinning is an optimal technique to create polymeric
membranes. Via electrospinning, polymer solutions are ejected
under electrical force; the uid jet is elongated and solidies to
ultrane bers before reaching a collector; those randomly
deposited ultrane bers form non-woven membranes.4 The
electrospun membranes have a high porosity and surface area-to-
volume ratio, resembling the extracellular matrix (ECM) structure.
More importantly, the pore size of the electrospun membranes, in
general, is less than the average cell size and previous studies have
shown that such small pores do not allow cell penetration.5
GBR membranes do not possess an active role in local bone
regeneration, and specically synthetic membranes are
inherently hydrophobic6,7 and biologically inert.8 Diﬀerent
strategies can be adopted to overcome these drawbacks. The
development of new materials based on polymeric compos-
ites5,9 or graphene/graphene oxide composites10,11 are prom-
ising approaches, leading to the proliferation and osteogenic
diﬀerentiation of osteoblastic cells. An alternative strategy is
the incorporation of osteostimulatory compounds. The
incorporation of growth factors, such as bone morphogenetic
proteins (BMPs) is a rst choice due to their potent osteoin-
ductive eﬀect.12,13 However, their incorporation is limited by
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their inactivity when in contact with organic solvents or at
physiological conditions, uncontrolled release which can lead
to supraphysiologic concentrations and high cost.14,15 Small
osteogenic pharmaceutical drugs have shown to be a prom-
ising alternative, showing higher chemical stability and
a lower cost.16 Simvastatin (SV) is used to treat hypercholes-
terolemia and hyperlipidemia.17,18 Recently, it has also been
reported that SV directly promotes osteoblastic diﬀerentiation
and improves new bone formation by increasing the expres-
sion of bone morphogenetic protein-2 (BMP-2), alkaline
phosphatase (ALP), osteocalcin and collagen type 1 (COL1)
mRNAs in osteoblast-like cells and stem cells. The mechanism
associated with the inuence of simvastatin on the osteogenic
diﬀerentiation is not fully understood. However, recent
studies point out to a direct action of simvastatin in the acti-
vation of the Wnt/b-catenin signaling pathway, which is
involved in the diﬀerentiation of mesenchymal stem cells
(MSCs) and the proliferation, diﬀerentiation, mineralization
and apoptosis of osteoblastic cells.19 Promotion of angiogen-
esis by SV has also been reported.20 SV has been incorporated
in diﬀerent materials, including calcium-phosphate particles
and granules,20,21 metallic substrates22,23 and polymeric parti-
cles,24 micelles25 and scaﬀolds.26,27 Electrospun polymeric
membranes containing SV have been previously developed,28,29
but SV release from these membranes occurred as fast as
within 8 days,20,21,24,26 which does not match the pace of bone
regeneration (12 weeks).30 Consequently, the need for
a system achieving prolonged SV release is apparent.
Thermal treatments such as annealing,31 quenching,32 or
aging33 are commonly used to modify the physicochemical
properties of polymers. By heating a polymer to a temperature
slightly above its cold crystallization temperature (Tcc), it is
possible to increase its overall crystallinity. Here, our goal was to
develop an electrospun poly(L-lactic acid) (PLLA) membrane for
prolonged SV release. PLLA was chosen due to its biocompati-
bility, biodegradability, and appropriate mechanical and phys-
icochemical properties. More specically, PLLA showed no
obvious degradation within 3 months, which ensures the
mechanical stability of the GBR membranes during the treat-
ment period.34,35 PLLA is a semi-crystalline polymer and it has
been reported that the change of crystallinity of a polymeric
drug carrier signicantly aﬀects the release of drugs.36–40
Consequently, we utilized thermal treatment of the electrospun
PLLA membranes to increase its crystallinity and control the
drug release. The morphological properties of the membranes
were evaluated by scanning electron microscopy (SEM), physi-
cochemical properties were analyzed by attenuated total
reectance-infrared spectroscopy (ATR-IR), X-ray diﬀraction
(XRD) and diﬀerential scanning calorimetry (DSC). The release
prole of simvastatin from the membranes with or without
thermal treatment was evaluated by in vitro incubation in near-
physiological conditions at 37 C. The cellular osteogenic
response to the membranes and biological activity of SV was
determined by in vitro culture of the diﬀerent membranes with
rat bone marrow stromal-cells (rBMSCs) and evaluating cell
morphology, proliferation, and osteogenic diﬀerentiation over
culture time.
Materials and methods
Preparation of polymeric solutions and fabrication of
electrospun membranes
Poly(L-lactic acid) (PLLA; Purasorb PL65®; Corbion, The Neth-
erlands) solutions were prepared by dissolving the polymer in
1,1,1,3,3,3-hexauoroisopropanol (HFIP; Fluorochem, UK) to
a concentration of 3% w/v. Solutions containing simvastatin
(SV; Sigma-Aldrich, USA) were prepared by dissolving the SV
(5% w/w to PLLA) and PLLA in HFIP and le to be stirred
overnight. Membranes were prepared by electrospinning
(Advanced Surface Technology BV, The Netherlands) and the
following parameters were applied: needle diameter ¼ 1.2 mm,
feeding rate ¼ 2.0 ml h1; distance between the needle and the
collector ¼ 20 cm; voltage ¼ 19.25 kV.
Thermal treatment of the membranes was performed in an
oven at 80 C for 16 hours.
Four diﬀerent membranes were produced: pure PLLA
membranes (PLLA); PLLA membranes subjected to the thermal
treatment (PLLA HT); PLLA membranes containing simvastatin
(PLLA + SV); PLLA membranes containing simvastatin and
subjected to the thermal treatment (PLLA + SV HT).
Morphological and structural evaluation
The morphology of the membranes was observed using scan-
ning electron microscopy (SEM; SIGMA 300; Zeiss, The Neth-
erlands). Samples were xed into aluminum stubs with carbon
tape and sputter coated with chromium (thickness of 20 nm).
The chemical prole of the membranes was assessed by
attenuated total reectance-infrared spectroscopy (ATR-IR;
UATR two; PerkinElmer, The Netherlands) with a resolution of
4.0 cm1 and a scanning range from 400 cm1 to 4000 cm1.
X-ray diﬀraction (XRD; X'pert3 powder; PANalytical, The
Netherlands) was performed to determine the crystallographic
prole of the membranes. Electrospun membranes as a thin
planar layer were placed on a glass holder and scanned. XRD
spectra were registered at 40 kV, 30 mA (Cu-Ka radiation with
a wavelength of 1.54 A˚) and a 2q between 10 and 40, at a step
size of 0.005.
Crystallinity was determined by modulated diﬀerential scan-
ning calorimetry (DSC; Discovery®; TA instruments, The Neth-
erlands). For DSC analysis, samples were placed in perforated
aluminum pans, to avoid overpressure, and scanned from 20 to
200 C at a heating rate of 2 C min1. The degree of crystallinity
(cc%) was calculated considering the ratio between the experi-
mental heat of melting (DHm) minus the cold crystallization heat
(DHcc) and the heat of melting of 100% crystalline PLLA
ðDHm ¼ 93:6 J g1Þ,41 according to the following equation:
cc% ¼
½DHm  DHcc
DHm
Release of simvastatin (SV) in an aqueous medium
Membranes containing SV with or without thermal treatment
(z0.8 mg each sample) were immersed in 1 ml of PBS at 37 C.
The supernatant was collected at predetermined time points,
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 28546–28554 | 28547
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being themedium renewed with 1ml of PBS. The amounts of SV
released were determined by liquid chromatography-mass
spectrometry (LC-MS). The conditions of analysis were the
following:
LC-MS was performed with a mobile phase that consisted of
acetonitrile (ACN) + 0.1% v/v formic acid and water (H2O) +
0.1% v/v formic acid, with a gradient of acetonitrile from 5 to
100% for 30 min and a ow rate of 0.2 ml min1. Charged ions
([simvastatin + H]+ atm/z¼ 420.57 and [simvastatin acid + H]+ at
m/z ¼ 437.59) were analyzed in order to determine the amount
of simvastatin present in the samples.
The release of SV was tted according to the Higuchi and
Korsmeyer–Peppas mathematical kinetic models.
In vitro cell culture
rBMSCs were cultured with the membranes and their osteosti-
mulatory potential evaluated. rBMSCs were isolated from
healthy male Wistar rats with Radboudumc Animal Ethics
Committee approval (RU-DEC 2014-157). Cell culture medium
and all supplements were purchased from Gibco (Gibco®, Life
Technologies, USA), except the fetal bovine serum (FBS; Sigma-
Aldrich, USA). rBMSCs were isolated and cultured using
a method adapted fromManiatopoulos et al.42 The tibia of male
Wistar rats were extracted, and epiphyses were cut oﬀ. Cells
were ushed out of the remaining diaphyses using cell culture
medium consisting of a-MEM supplemented with 10% v/v fetal
calf serum, 50 mg ml1 ascorbic acid, 108 M dexamethasone,
50 mg ml1 gentamycin and 10 mM sodium b-glycer-
ophosphate. The ush-out of the two tibias was cultured for one
day in three 75 cm2 culture asks in a humidied incubator (5%
CO2; 37 C), aer which the medium was refreshed to remove
non-adherent cells. The osteogenic potential of the cells was
assessed by culturing rBMSCs with an osteogenic medium for
28 days, presenting the cells mineralization capability.
A preliminary study was rstly performed to evaluate the
cytotoxicity of simvastatin. Briey, rBMSCs were cultured in
a growth medium (a-MEM supplemented with 10% v/v FBS, 100
units per ml penicillin, and 100 mg ml1 streptomycin) con-
taining diﬀerent concentrations of simvastatin (4200 ngml1 or
z105 M, 420 ng ml1 or z106 M, 42 ng ml1 or z107 M,
and 4.2 ng ml1 orz108 M) at a cell density equal to 2  104/
cm2 and incubated in a humidied incubator (37 C, 5% CO2),
cytotoxicity was evaluated both by visual examination with an
optical microscope (DM IL LED, Leica, The Netherlands), for the
cells cultured at 3 days, 14 days and 28 days, and by an
AlamarBlue® viability test (Molecular Probes™, Invitrogen®,
Thermo Fisher Scientic, Bleiswijk, The Netherlands) aer 3, 7,
14, 21 and 28 days, according to themanufacturer's instructions
to obtain quantitative data on cellular activity. Viability
percentages are relative to a positive control, where rBMSCs
were cultured in an osteogenic medium (a-MEM supplemented
with 10% v/v FBS, 50 mg ml1 ascorbic acid, 108 M dexa-
methasone, 10 mM sodium b-glycerophosphate and 100 units
per ml penicillin + 100 mg ml1 streptomycin).
For the cell culture experiments, electrospun membranes
were rst disinfected with Argon plasma for 5 minutes (plasma
cleaner/sterilizer PDC-001; Harrick, USA). rBMSCs were stati-
cally seeded in 24-well adherent culture plates with growth
medium at a cell density equal to 2  104/cm2 and incubated in
a humidied incubator (37 C, 5% CO2), allowing the cells to
adhere to the bottom of the wells. Aer 24 hours, membranes
were placed in cell culture inserts (Thincert™, Greiner Bio-one,
The Netherlands) and indirectly cultured with the cells. The
diﬀerent groups and conditions of culture are described in
more detail in Table 1.
rBMSCs DNA quantication and ALP (alkaline phosphatase)
activity measurements (n ¼ 3) were performed at 3 days, 7 days,
14 days, 21 days and 28 days of co-culture as described previ-
ously.43 Briey, cells were washed with PBS twice, collected and
immersed in 1 ml of Milli-Q water. Aerward, sonication and
three freeze–thaw cycles were performed. DNA content in the
supernatant was measured using a Quant-IT™ PicoGreen® ds-
DNA assay kit (Invitrogen; The Netherlands) according to the
manufacturer's instructions. In a 96-well plate, 100 ml of sample
or standard were added to a working solution. The plates were
incubated at room temperature in the dark for 5 minutes and
uorescence read (excitation: 485/20 nm; emission: 530/25 nm).
ALP activity of the same sample was measured by a p-nitrophenyl
phosphate (4-NP; Sigma-Aldrich, USA) colorimetric assay,
according to the manufacturer's instructions. 80 ml of samples or
standards were added to 20 ml of buﬀer and 100 ml of the
substrate. The mixture was incubated for 60 minutes at 37 C.
Aerward, 100 ml of 0.5 M NaOH solution was added to stop the
reaction. Absorbance at 405 nm was read and ALP activity
normalized according to the DNA content for each sample.
To observe the cellular morphology, cells were directly
cultured on the membranes with the specic medium indicated
in Table 1. Samples were collected at 3 days, 14 days and 28
days. A 2% v/v solution of glutaraldehyde (glutaraldehyde
solution 25%; Merck; Germany) was used to xate the cells and
ethanol at graded concentrations (70%, 80%, 90%, 96% and
100% v/v) was used for dehydration. Finally, samples were
covered with tetramethylsilane (TMS; $99.0% GC; Sigma-
Aldrich; USA) and prepared for SEM observation as referred
previously.
Statistical analysis
Fiber diameter was estimated from the corresponding SEM
images using ImageJ soware (National Institutes of Health,
USA). Twenty diﬀerent measurements were taken from 5
diﬀerent regions of each electrospun membrane (n¼ 100). Data
were reported as mean  standard deviation (SD). Statistical
analysis was carried out by using one-way analysis of variance
(ANOVA) combined with a Tukey's multiple comparison post-
Table 1 Groups for in vitro cell culture experiments
Group Composition
PLLA Membrane + growth medium+ 10 mM b-GP
PLLA + SV Membrane + growth medium+ 10 mM b-GP
PLLA + SV HT Membrane + growth medium+ 10 mM b-GP
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hoc test. Diﬀerences were considered signicant at p < 0.05.
Statistical diﬀerences in crystallinity of the diﬀerent samples (n
¼ 3) were analyzed using an unpaired t-test with Welch's
correction, calculated with Prism 6.01 (GraphPad Soware, Inc.;
USA). Data were reported as mean  standard deviation (SD).
Diﬀerences were considered signicant at p < 0.05. DNA content
and ALP activity (n ¼ 3) were analyzed using Prism 6.01 and
performing a two-way ANOVA signicance test combined with
a post-hoc Tukey's multiple comparison test. Data were reported
asmean standard deviation (SD). Diﬀerences were considered
signicant at p < 0.05.
Results
Morphological and structural evaluation of electrospun
membranes containing SV
Fig. 1 shows the morphology of the electrospun PLLA
membranes with and without SV before and aer thermal
treatment (HT). All membranes are composed of micrometric
bers, with a small decrease of the diameter of the bers when
the drug was incorporated (1.4  0.14 mm for PLLA; 1.3  0.11
mm for PLLA HT; 1.0  0.10 mm for PLLA + SV; 0.9  0.07 mm for
PLLA + SV HT). No noticeable changes in the morphology of the
bers were detected when SV was incorporated (Fig. 1c and d).
Membranes subjected to the thermal treatment (PLLA HT and
PLLA + SV HT) present a similar morphology when compared
with their non-thermal treated counterparts (PLLA and PLLA +
SV), although some deformation was visible of the bers
(Fig. 1b-red square and Fig. 1d-red square).
The chemical prole of themembranes was analyzed by ATR-
IR (Fig. 2). The spectra were similar for all membranes, showing
the characteristic peaks of PLLA highlighted with red lines:
1751 cm1 (carbonyl group); 1000–1450 cm1 (ether groups)
and 870 cm1 (alkyl groups).32,44,45 No characteristic peaks
related to the presence of SV were detected, either before or aer
thermal treatment. Further, thermal treatment did not aﬀect
the chemical composition of the membranes, with no signi-
cant changes in the polymeric backbone.
Fig. 3 presents the XRD proles for the diﬀerent membranes.
Samples without thermal treatment showed no sharp peaks on
the XRD spectra. Membranes with thermal treatment showed
a peak at approximately 2q ¼ 16 (red arrows, Fig. 3), repre-
senting the characteristic peak of the crystal structure of the
a form of PLLA.46
Fig. 4 shows the crystallinity percentage of the diﬀerent elec-
trospunmembranes. As expected, crystallinity increased aer the
membranes were subjected to thermal treatment, shown by XRD
(42  7.8% vs. 58  4.4% for PLLA without SV and 38  3.0% vs.
62  1.1% for PLLA with SV). On the other hand, the incorpo-
ration of SV did not aﬀect the crystallinity of PLLA. The repre-
sentative DSC spectra of each group are shown in Fig. S1† and the
correlated thermal properties are summarized in Table S1.† The
glass transition temperature (Tg) decreased when SV was incor-
porated (54  1.1 C vs. 46  0.1 C for PLLA and PLLA + SV,
respectively). Tg of membranes subjected to thermal treatment
was not detectable considering the total heat ow (Fig. S1†).
However, when examining the data obtained with the reversing
heat ow, the Tg for these membranes was determined (Fig. S2†).
A substantial increase of the Tg values due to thermal treatment
was detected (73  0.3 C and 73 1.0 C for PLLA HT and PLLA
+ SV HT respectively). The melting temperature (Tm) was not
aﬀected by the incorporation of SV or by the thermal treatment.
Drug release from PLLA membranes
The release proles of the membranes containing SV are pre-
sented in Fig. 5. No initial burst release of SV was detected for
both membranes. A higher SV release from PLLA without
Fig. 1 SEM images of electrospun ﬁbers 5000 (red squares) and 50 000. (a) PLLA (b) PLLA HT (c) PLLA + SV (d) PLLA + SV HT.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 28546–28554 | 28549
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thermal treatment was detected. SV released at a fast speed
within the rst 5 days and continued to release at a constant
slow speed up to 28 days, except that PLLA + SV showed
a sudden increase in the amount of SV released at week 4. Not
all the incorporated SV was released from PLLA membranes
aer 4 weeks: 11 1.9% SV released for PLLA + SV and 3 0.8%
for PLLA + SV HT.
SV release data were tted according to two well-established
drug release models: the Higuchi model and the Korsmeyer–
Peppasmodel. As shown in Fig. S3,† SV release correlated highly
with both models, although the Korsmeyer–Peppas model
presented a higher correlation for both membranes (R2 ¼ 0.98
vs. R2 ¼ 0.97 for Higuchi model). The Korsmeyer–Peppas model
tting showed diﬀerent release exponents (n): n¼ 0.56 for PLLA
+ SV and n ¼ 0.47 for PLLA + SV HT.
In vitro study with rBMSCs
rBMSCs were cultured in a proliferative medium containing
simvastatin at diﬀerent concentrations for 28 days, and cyto-
toxicity was evaluated using light microscopy and AlamarBlue
assays (Fig. S4 and S5†). Cellular proliferation occurred mainly
Fig. 3 XRD spectra of electrospun membranes. Red arrows indicate the peak of the a form of PLLA.
Fig. 2 ATR-IR spectra of electrospun membranes. Red lines represent the main peaks belonging to PLLA.
28550 | RSC Adv., 2018, 8, 28546–28554 This journal is © The Royal Society of Chemistry 2018
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for the cells cultured with simvastatin concentrations of 42 ng
ml1 (107 M) and 4.2 ng ml1 (108 M). Simvastatin concen-
trations above 420 ng ml1 (z106 M) resulted in substantial
cytotoxicity, leading to cellular death (Fig. S4†) and low viability
percentages (Fig. S5†).
rBMSCs were directly seeded on the diﬀerent electrospun
membranes with the purpose to analyze the cellular
morphology and response. Fig. 6 shows the images obtained by
SEM aer 3, 14 and 28 days of culture. Aer 3 days of culture,
cells showed adherence to the membranes. At 14 days of
culture, the number of cells increased signicantly, covering
almost the entire surface of the membranes. At 28 days, the
membranes were completely covered by the cells and a thick cell
layer on top of the membranes was observed.
Fig. 7 shows the DNA amount and ALP-activity obtained
upon indirect in vitro culture experiments. An increase in the
DNA amount with time was observed for all groups. At indi-
vidual time points, no signicant diﬀerences between groups
were observed. PLLA + SV HT membranes evoked an increase in
ALP-activity up to 7 days followed by a decrease. Further, PLLA +
SV HT membranes induced the highest ALP-activity levels
among all groups (Fig. 7b).
Discussion
We here aimed to incorporate an osteostimulatory drug, sim-
vastatin (SV), in a PLLA electrospun membrane and prolong its
release, with the ultimate objective of creating amembrane with
suitable biological properties for GBR applications. SV was
chosen not only due to its well documented promotion of in
vitro osteogenic diﬀerentiation47,48 and bone regeneration, both
in in vivo49,50 and in clinical studies,51 but also because it
possesses a high thermal stability (Tm of 139 C), and good
solubility in organic solvents.52,53 The eﬀect of PLLA crystallinity
on the release of SV was investigated. In order to increase PLLA
crystallinity, membranes were treated at 80 C for 16 hours. SV
release kinetics showed that variations in PLLA crystallinity can
be used to control SV release. In vitro cell culture assays
demonstrated a continuous proliferation of cells over time for
all compositions, with a signicant increase in ALP-activity
levels of osteogenic cells by membranes containing SV.
PLLA membranes containing SV were produced by electro-
spinning. Morphological evaluation of the membranes showed
the formation of micrometric electrospun bers with a smooth
surface and a decrease of the diameter of the bers when SV was
incorporated. The decrease in ber diameter is probably related
to an increase in the conductivity of the polymeric solution for
the compositions containing SV, leading to a decrease in ber
diameter during electrospinning.54 Thermal treatment did not
aﬀect the surface morphology or the diameter of the bers,
although limited ber deformation could be noticed.
Similar ATR-IR spectra were obtained for all the membranes
due to the overlap of characteristic infrared bands of SV with
those of PLLA.52,55 Further, the similar spectra of membranes
with or without thermal treatment indicate that the thermal
treatment did not change the chemical structure of the elec-
trospun membranes.
XRD and DSC results conrmed that the thermal treatment
used in this study increased the crystallinity of PLLA
membranes. It has been shown previously that an increase in
polymer crystallinity due to thermal exposure leads to a slower
diﬀusion of the drugs because the crystalline domains function
as a physical barrier and reduce polymeric degradation.56,57 The
results from our study corroborate these data. The amount of SV
released from PLLA + SV membranes was approximately 2 times
higher than the membranes subjected to the thermal treatment
(PLLA + SV HT), demonstrating the primary role of crystallinity
in controlling the release of SV. Release data of both
membranes were tted according to two kinetic models (i.e. the
Higuchi model and the Korsmeyer–Peppas model) in order to
understand the drug release mechanism(s).58,59 The Higuchi
Fig. 5 Cumulative release of simvastatin in PBS at 37 C (a) cumulative mass (b) cumulative percentage.
Fig. 4 Crystallinity of electrospun membranes. * ¼ p < 0.05;
** ¼ p < 0.01.
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kinetic model is an ideal model, which considers the release of
a drug from a homogeneous solid matrix, where the diﬀusion of
the drug is constant and phenomena like polymer swelling and
dissolution are negligible. The Korsmeyer–Peppas kinetic
model is more complex and diﬀerent release mechanisms are
considered. According to the Korsmeyer–Peppas model, for
cylindrical structures an n # 0.45 corresponds to ckian-based
diﬀusion, an 0.45 < n < 0.89 to non-ckian (anomalous) diﬀu-
sion, an n ¼ 0.89 to case II (relaxational) transport, and n > 0.89
to super case II transport, the two last mechanisms being
related to polymer swelling and erosion. For both models, the
correlation coeﬃcient was high, although slightly higher for the
Korsmeyer–Peppas kinetic model. The Korsmeyer–Peppas
model was considered as more accurate to explain the mecha-
nism(s) related to the in vitro release of SV. Considering that
ideally the electrospun bers possess a cylindrical geometry, the
determined n values demonstrate that PLLA + SV membranes
exert an anomalous non-ckian diﬀusion of SV to the medium
(n > 0.45), likely due to ber erosion phenomena. PLLA + SV HT
membranes, on the other hand, present an n value very close to
0.45, suggesting a diﬀusion of SV that follows the Fick's law.60
rBMSCs were cultured with pure and SV-loaded PLLA
membranes with or without thermal treatment (PLLA, PLLA +
SV and PLLA + SV HT). The mass of the membranes utilized in
Fig. 6 SEM images of rBMSCs cultured on the membranes at 150 (red squares) and 1000.
Fig. 7 In vitro culture of rBMSCs. (a) DNA concentration (b) ALP activity. * ¼ p < 0.05; **** ¼ p < 0.0001.
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culture was calculated based on the SV release prole so that the
concentration of SV in the medium was within the reported
range capable of inducing an osteogenic response.20,25,61,62
Should be mentioned that the potential cytotoxicity of simvas-
tatin was also considered. Viability tests, where rBMSCs were
cultured in medium containing diﬀerent concentrations of
simvastatin, were performed on an early phase of this study
(Fig. S4 and S5†) and the following assays were performed
taking into account the viability results obtained.
The purpose of these experiments was to evaluate if (i) the
membranes could induce an osteogenic response from the
rBMSCs, and (ii) the diﬀerences in the amount of drug released
from the membranes with or without thermal treatment would
aﬀect osteogenic diﬀerentiation. Morphological observations
indicated that rBMSCs adhered and proliferated on all
membranes over time. The results of DNA assay were consistent
with this nding. The DNA results further demonstrated that
the tested membranes did not evoke a cytotoxic eﬀect. More-
over, SV incorporation followed by thermal treatment induced
an increased osteogenic response from rBMSCs, demonstrated
by a signicantly increased ALP-activity for the cells cultured on
such membranes (PLLA + SV HT). A suppression of an initial
burst-release, combined with the signicantly lower amounts of
SV present in the medium, due to its more sustained release
from these membranes, appeared to be benecial for the oste-
ogenic diﬀerentiation of pre-osteoblastic cells.25,60 In this study
a non-osteogenic medium supplemented with b-glycer-
ophosphate was used to solely evaluate the eﬀect of SV on the
osteogenic diﬀerentiation of rBMSCs, without the inuence of
known osteoinductive compounds as ascorbic acid or dexa-
methasone. Also, we focused on analyzing the ALP-activity
levels, since SV is known to have a major eﬀect in the expres-
sion of this protein and a signicant impact on the early stages
of the osteogenic diﬀerentiation of osteoblastic cells.50 Further
studies should be performed in order to evaluate the eﬀect of
the systems developed on the mineralization capability of
rBMSCs.
Conclusion
We developed electrospun PLLA membranes with enhanced
osteostimulatory properties by incorporating simvastatin (SV)
and modied the SV release prole by varying the PLLA crys-
tallinity. Thermal treatment successfully increased the PLLA
crystallinity for all compositions without signicantly changing
the chemical properties and morphology of the electrospun
bers. A markedly more sustained release of SV was observed
upon the thermal treatment to increase the PLLA crystallinity.
In vitro culture of PLLA membranes with rBMSCs demonstrated
that the membranes are cytocompatible, with an increase in cell
proliferation over time. PLLA + SV HT induced an osteogenic
response from rBMSCs, with signicantly increased ALP-activity
levels demonstrating both a preservation of biological activity of
SV and an appropriate SV release prole. Thermal treatment to
increase PLLA crystallinity in electrospun membranes can be
used to control SV release and render these membranes bio-
logically active.
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